Search Results - "Bodini, G."

The natural history of gastro-esophageal reflux disease: a comprehensive review by Savarino, E., de Bortoli, N., De Cassan, C., Della Coletta, M., Bartolo, O., Furnari, M., Ottonello, A., Marabotto, E., Bodini, G., Savarino, V.

“…SUMMARY Gastroesophageal reflux disease (GERD) is a common disorder of the upper gastrointestinal tract which is typically characterized by heartburn and acid…”
Get full text

Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? by Tolone, S., De Bortoli, N., Marabotto, E., Cassan, C., Bodini, G., Roman, S., Furnari, M., Savarino, V., Docimo, L., Savarino, E.

“…Background The role of esophagogastric junction contractile integral (EGJ‐CI) as assessed by high‐resolution manometry (HRM) is unclear. We aimed to correlate…”
Get full text

Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease by Savarino, E., Bodini, G., Savarino, V.

Get full text

Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease by Furnari, M., Bodini, G., Giannini, E. G., Savarino, V.

Get full text

Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study by Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., Armuzzi, A.

“…In recent years, improvement of Health-Related Quality of Life (HRQoL) in Ulcerative colitis (UC) has become a relevant measure for treatment efficacy. We…”
Get full text

Letter: biological therapies are effective for prevention of post‐operative Crohn's disease recurrence by Bodini, G., De Cassan, C., Savarino, V., Savarino, E.

Get full text

P.07.14 BIOLOGICAL THERAPY IS ABLE TO MODIFY THE DISEASE PROGRESSION OF CROHN'S DISEASE PREVENTING ITS LONG-TERM ASSOCIATED DISABILITY – A STUDY PERFORMED USING THE LÉMANN SCORE by Bodini, G, Giannini, E, Savarino, V, De Maria, C, Baldissarro, I, Savarino, E

Get full text

OC.02.7 ADALIMUMAB TROUGH LEVELS AT WEEK EIGHT AS PREDICTIVE FACTOR OF LONG TERM CLINICAL REMISSION by Pellegatta, G, Moscatelli, A, Savarino, V, Savarino, E, Bodini, G, Baldissarro, I, Giannini, E.G

Get full text

P.07.7 CROHN'S DISEASE IS A REAL TIME SENSITIVE EVOLUTIVE PATHOLOGY BASED ON LÉMANN INDEX? PRELIMINARY DATA FROM A TERTIARY PEDIATRIC IBD CENTER by Bodini, G, Arrigo, S, Bizzocchi, A, Giannini, E, Savarino, V, Savarino, E, Barabino, A

Get full text

P.11.6: Biological Therapy is Able to Halt Crohn’s Disease Progression: A Prospective, Long Term Study Using the Lémann Index by Bodini, G, Pellegatta, G, Giannini, E, Savarino, V, De Maria, C, Baldissarro, I, Savarino, E

Get full text

P.11.10: Does Lémann Index Reflect the Quality of Life in Crohn’s Disease Patients on Treatment with Biological Therapy? by Pellegatta, G, Bodini, G, Giannini, E, De Maria, C, Baldissarro, I, Savarino, V, Savarino, E

Get full text

OC.02.6 IDENTIFICATION OF A CUT-OFF FOR PERSISTENT ANTI-INFLIXIMAB ANTIBODIES AS A PREDICTOR OF RESPONSE TO INFLIXIMAB MONOTHERAPY by Del Nero, L, Bodini, G, Giannini, E.G, Savarino, V, De Maria, C, Baldissarro, I, Savarino, E

Get full text

P.07.15 INFLIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION by Bodini, G, Del Nero, L, Giannini, E, De Maria, C, Baldissarro, I, Savarino, V, Savarino, E

Get full text

PC.01.5 A NEW SUB-CLASSIFICATION OF ESOPHAGO-GASTRIC JUNCTION MORPHOLOGY TYPE I HELPS TO BETTER RECOGNIZE PATIENTS WITH A POSITIVE IMPEDANCE-PH MONITORING by Tolone, S, Savarino, E, De Bortoli, N, Furnari, M, Frazzoni, M, Martinucci, I, Bodini, G, Della Colletta, M, Bartolo, O, Parisi, S, Bondanese, M, Savarino, V, Docimo, L

Get full text

OC.07.2 FUNCTIONAL HEARTBURN OVERLAPS WITH IRRITABLE BOWEL SYNDROME MORE OFTEN THAN GERD. DEVELOPMENT OF PREDICTIVE MODELS WITH NOMOGRAMS by De Bortoli, N, Frazzoni, L, Savarino, E.V, Martinucci, I, Frazzoni, M, Tolone, S, Marabotto, E, Furnari, M, Bodini, G, Fuccio, L, Bellini, M, Savarino, V, Marchi, S

Get full text

Impact of evidence‐based medicine on the treatment of patients with unresectable hepatocellular carcinoma by GIANNINI, E. G., BODINI, G., CORBO, M., SAVARINO, V., RISSO, D., DI NOLFO, M. A., DEL POGGIO, P., BENVEGNÙ, L., FARINATI, F., ZOLI, M., BORZIO, F., CATURELLI, E., CHIARAMONTE, M., TREVISANI, F.

“…Aliment Pharmacol Ther 31, 493–501 Summary Background  A randomized controlled trial performed by the Barcelona Clinic Liver Cancer (BCLC) published in 2002…”
Get full text

P.13.17 INTRA- AND INTEROBSERVER AGREEMENT BETWEEN ENDOSCOPISTS AND PATHOLOGISTS FOR DETECTION OF GASTRIC INTESTINAL METAPLASIA BY MEANS OF NARROW BAND IMAGING WITH MAGNIFYING ENDOSCOPY by Gemignani, L, Savarino, E, Dulbecco, P, Giambruno, E, Bodini, G, Furnari, M, Mastracci, L, Grillo, F, Giacchino, M, Gianiorio, F.E, Savarino, V

Get full text

P.01.16 ADALIMUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE AND MESALAMINE AT PREVENTING POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE – A RANDOMIZED TRIAL by Savarino, E, Bodini, G, Dulbecco, P, Assandri, L, Bruzzone, L, Mazza, F, Sammito, G, Fazio, V, Giambruno, E, Gemignani, L, Savarino, V

Get full text

P.07.18 EFFICACY OF PARTIALLY HYDROLYZED GUAR GUM TO REDUCE METHANE EXCRETION AND CLINICAL MANIFESTATION OF SUBJECTS SUFFERING FROM IRRITABLE BOWEL SYNDROME by Furnari, M, Bruzzone, L, Savarino, E, Gemignani, L, Giambruno, E, Bodini, G, Dulbecco, P, Savarino, V

Get full text

OC.06.5 RELATIONSHIP BETWEEN DRUG SERUM CONCENTRATION AND CLINICAL ACTIVITY IN PATIENTS WITH CROHN'S DISEASE WHO ACHIEVED REMISSION WITH ADALIMUMAB by Bodini, G, Savarino, V, Fazio, V, Assandri, L, Gemignani, L, Dulbecco, P, Giambruno, E, Savarino, E

Get full text